Erratum

Figures & data

Table 9. Safety results of Phase III studies comparing sublingual sufentanil tablet system with intravenous patient-controlled analgesia with morphine sulfate or placebo system.

Safety parameter	Orthopedic^† and open abdominal surgeries [35]		Open abdominal surgery [36]		Orthopedic surgery^† [38]
	SSTS (n = 177)	iv. PCA MS (n = 180)	SSTS (n = 114)	Placebo (n = 58)	SSTS (n = 315)	Placebo (n = 104)
Possibly or probably related AEs occurring in ≥5% in any group, (%)
Nausea	43	40	14	22	35^*	22
Vomiting	13	11	4	3	11	6
Oxygen saturation decreased	10	9	4	2	7	3
Dizziness	6	3	3	2	5	1
Pruritus	4	8	4	0	5^*	0
Constipation	11	8	1	0	5	1
Headache	8	7	1	0	4	6
Hypotension	6	11	1	0	4	2

* p < 0.05.

† Total hip or total knee arthroplasty.

AE: Adverse event; iv. PCA MS: Intravenous patient-controlled analgesia with morphine sulfate; SSTS: Sublingual sufentanil tablet system.